Key facts
- Notable investors include Chengdu High-Tech Investment, Qingdao Hi-Tech Venture-Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AblinkBiotech
- ·The full record, as it builds
Funding rounds
No funding rounds for AblinkBiotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AblinkBiotech
Developer of biological materials intended for therapeutic discovery. The company offers large-scale synthetic libraries, phage and mammalian cell display technologies, and AI-driven modeling of sequence-structure-activity relationships, enabling global biopharmaceutical enterprises to accelerate screening, optimize candidates, validate data at high throughput, and significantly reduce development timelines while expanding diversity in advanced therapeutic innovation.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 9
- Website
- ablinkbiotech.com/
- Ownership
- Privately Held (backing)
AblinkBiotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AblinkBiotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AblinkBiotech in its N-PORT filings yet. We sweep new filings monthly.